Navigation Links
Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
Date:12/14/2010

with only 4 weeks of Peg-IFN;

-- PSI-7977 400mg QD in combination with RBV for 12 weeks, with only 8 weeks of Peg-IFN;

-- PSI-7977 400mg QD in combination with Peg-IFN and RBV for 12 weeks.

Patients will be stratified by HCV genotype and IL28B status to ensure balance across cohorts.

Pharmasset anticipates reporting interim data from this trial in the first half of 2011.

About Pharmasset Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys(R) plus Copegus(R) and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that has recently initiated dosing in a Phase 2b study in patients with HCV genotypes 1, 2, or 3, and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 7-day monotherapy study. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 19
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... GRAND RAPIDS, Mich. , Jan. 15, 2014 As ... of the flu virus, select Meijer pharmacies in ... and strep throat to eligible patients, enabling Meijer pharmacists to ... under strict protocol set by a physician participating in the ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
... Calif., April 13, 2011 Two new studies published ... and Related Diseases, a peer-reviewed journal, add to ... the LAP-BAND® Adjustable Gastric Banding System, made by Allergan, ... and effective weight-loss procedure. One study concluded that laparoscopic ...
... 13, 2011 / PRNewswire / -- ... today announced the Ion OneTouch System, an automated sample preparation system ... complexity, reduces hands-on time to five minutes and offers walk-away ... introductory price of under $5,000; the first shipments will be ...
Cached Medicine Technology:New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 2New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 3New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 4New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 5New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 6New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 7New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 8New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 9Life Technologies Announces an Automated Sample Preparation System for its Ion PGM™ Sequencer 2Life Technologies Announces an Automated Sample Preparation System for its Ion PGM™ Sequencer 3Life Technologies Announces an Automated Sample Preparation System for its Ion PGM™ Sequencer 4
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently ... molecule in metastatic breast cancer reduces both the growth ... BRI scientists have found in models of the disease ... - 80 percent and can keep the tumor from ... five-year grant comes from the National Cancer Institute of ...
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2
... interventions to Vietnamese populationsFREMONT, Calif., March 18 The ... NCCC ) ... first-of-its-kind study of interventions to improve colon cancer screening ... to non-Hispanic whites. NCCC Scientist Bang Nguyen, Dr.P.H. ...
... successful projects. , ... Orinda, CA (PRWEB) March 18, ... allocates billions of dollars to the NIH, NSF, NIST, DOE and ... research facilities. These funds will be distributed to research institutions ...
... rate for combo surgery, , , WEDNESDAY, March 18 (HealthDay ... people who would benefit from a combined heart and ... "In the past, patients with end-stage heart failure having ... heart transplantation," Dr. Mark J. Russo, of Columbia University ...
... prostate cancer can reduce deaths by 20%, according to ... for Prostate Cancer (ERSPC) published online 1700 hours CET, ... world,s largest prostate cancer screening study and provides robust, ... effect of screening on prostate cancer mortality. , The ...
... a common medical condition characterized by convulsions and short ... people worldwide. But intractable epilepsy, which affects more than ... treatment and surgery, is arguably worse. ... unique nerve-stimulation treatment for intractable epilepsy reduced the number ...
... YORK, March 18 HMS Holdings Corp. (Nasdaq: ... at the Sidoti & Co. 13th Annual New York ... New York City.The Company will present on Wednesday, March ... is the leader in coordination of benefits and program ...
Cached Medicine News:Health News:Northern California Cancer Center Study Seeks to Improve Colon Cancer Screening in Vietnamese Communities 2Health News:Stimulus Spending Targets Modernization of the Nation's Research Infrastructure 2Health News:Stimulus Spending Targets Modernization of the Nation's Research Infrastructure 3Health News:Guidelines Suggested for Heart-Kidney Transplants 2Health News:PSA screening cuts deaths by 20 percent 2Health News:Unique nerve-stimulation device proves effective against epilepsy 2
Peapod Rongeur, 5.5 length 140 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
Mayfield Disposable Adult (plastic) Skull Pins are designed for rigid skeletal fixation....
... Karl Storz borescopes are rigid endoscopes for general ... lens system. The diameters of borescopes, i.e. rigid ... with viewing directions from 0 up to a ... zoom lens and wide angle view. Endoscopes with ...
Medicine Products: